Moreover, based on the observed increase in metabolic dependency of FGFR2 + ICC cells on fatty acid oxidation (FAO) following FGFR inhibitor treatment (Fig. 4b), we also explored the cooperative impact of suppression of FAO via treatment with etomoxir, a CPT1A inhibitor. This evidence concerns the gene CPT1A and intrahepatic cholangiocarcinoma.